

Bitte beachten Sie: Dieses Dokument wurde automatisch erstellt und ist kein Ersatz für das Originaldokument des Herstellers.

## Product Datasheet

### **VEGF Receptor 1 / VEGFR1 Antibody / FLT1, Clone: [VGR1T-1], Mouse, Monoclonal NSJ-V7024-20UG**

|                          |   |
|--------------------------|---|
| Artikelname              | VEGF Receptor 1 / VEGFR1 Antibody / FLT1, Clone: [VGR1T-1], Mouse, Monoclonal   |
| Artikelnummer            | NSJ-V7024-20UG  |
| Hersteller Artikelnummer | V7024-20UG  |
| Alternativnummer         | NSJ-V7024-20UG  |
| Hersteller               | NSJ Bioreagents   |
| Wirt                     | Mouse   |
| Kategorie                | Antikörper  |
| Applikation              | FACS, IF  |
| Spezies Reaktivität      | Human   |
| Immunogen                | Recombinant human protein was used as the immunogen for this VEGFR1 antibody.   |
| Produktbeschreibung      | VEGFR1 is high affinity receptors for vascular endothelial growth factors (VEGFs). On the basis of structural similarity to VEGFR1 and 2, it has been speculated that Flt-4 might represent a third receptor for either VEGF or a VEGF-related ligand.... |
| Klonalität               | Monoclonal  |
| Konzentration            | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide  |
| Klon-Bezeichnung         | [VGR1T-1]   |

|                        |  |
|------------------------|--|
| Isotyp                 | Mouse IgG1, kappa  |
| NCBI                   | <a href="#">2321</a>   |
| Puffer                 | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide   |
| Reinheit               | Protein G affinity chromatography  |
| Formulierung           | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide   |
| Target-Kategorie       | VEGF Receptor 1 / VEGFR1   |
| Antibody Type          | Primary Antibody   |
| Application Verdünnung | FACS: 1-2ug/million cells in 0.1ml, Immunofluorescence: 1-2ug/ml   |
| Anwendungsbeschreibung | Variations in protocols, secondaries and substrates may require the VEGFR1 antibody to be titered for optimal performance. |